Vyvgart shines in CIDP study, teeing up another potential nod for Argenx's pipeline in a product
you will need to google the titles above & below
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
########
16,000 people in USA suffer from CIDP - this is nowhere near 25% of Ig use & the article mentions some CIDP patients use Ig & some use corticosteroids & now Argenx Vyvgart looks like a successful treatment preventing relapse in over 60% of patients - so it's not the magic cure but a very effective treatment & extra option along with Ig & Corticosteroids
Argenx looks to be doing incredible work & will likely attract takeover interest from larger biotech companies - the enzyme based drug delivery system also looks very promising
If Argenx continues to develop targeted therapies it is good for patients & will provide insight into more potential refined or expanded uses of CSL Ig products if deemed worth investigating & modifying
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)